Procoralan Making a Strong Entry to the new ESC Guidelines for the Management of Heart Failure

Procoralan Making a Strong Entry to the new ESC Guidelines for the Management of Heart Failure PR Newswire PARIS, June 7, 2012 PARIS, June 7, 2012 /PRNewswire/ -- The new ESC guidelines for the diagnosis and management of heart failure include the heart ratelowering drug, Procoralan® (ivabradine) Less than 2 years after the publication in The Lancet of the SHIFT study results demonstrating its benefits in heart failure, Procoralan® is now integrated in the [1]new ESC guidelines for the management of heart failure. The guidelines, presented this week at the ESC's Heart Failure Congress in Belgrade, Serbia, have been updated for the first time since 2008. They make recommendations for treatment based upon evidence for established and new diagnostic tests, and therapies for heart failure. "The revised ESC Heart Failure guidelines aim to help physicians in everyday clinical medical decision-making and if implemented offer a real opportunity to improve the outcome of patients with this condition," commented John McMurray, Professor of Medical Cardiology at the University of Glasgow and principal author of the new ESC guidelines. Heart failure patients with elevated heart rates are at a significantly greater risk of death or hospitalisation, which both impacts patients' quality of life and ultimate outcome and puts pressure [2]on healthcare systems.